Ginkgo Bioworks Holdings (DNA) Operating Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Operating Margin came in at 366.51% in Q1 2026, down 15471.0% YoY from N/an in Q1 2025, and down 73.0% on a QoQ basis from 211.86% in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Operating Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Operating Margin data on file, last reported at 366.51% in Q1 2026.
- Quarterly Operating Margin fell 15471.0% year-over-year to 366.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 210.66% (down 711.0% YoY) and the FY2025 annual result came in at 185.29%, up 6125.0% from the prior year.
- Operating Margin retreated to 366.51% in Q1 2026, from 211.86% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 61.99% in Q3 2024 to a low of 986.38% in Q3 2022.
- A 5-year average of 322.01% and a median of 236.29% in 2024 frame the typical range for Operating Margin.
- The widest YoY moves for Operating Margin: up 89966 bps in 2022, down 95202 bps in 2022.
- Tracing DNA's Operating Margin over 5 years: stood at 234.89% in 2022, then surged by 69 bps to 73.27% in 2023, then tumbled by 222 bps to 236.29% in 2024, then advanced by 10 bps to 211.86% in 2025, then plunged by 73 bps to 366.51% in 2026.
- The last three Operating Margin figures came in at 366.51% (Q1 2026), 211.86% (Q4 2025), and 231.78% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | -290.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -290.47% |
| Mar 31, 2026 | -366.51% |
| Dec 31, 2025 | -211.86% |
| Sep 30, 2025 | -231.78% |
| Jun 30, 2025 | -132.13% |
| Mar 31, 2025 | -211.80% |
| Dec 31, 2024 | -236.29% |
| Sep 30, 2024 | -61.99% |
| Jun 30, 2024 | -396.66% |
| Mar 31, 2024 | -469.12% |
| Dec 31, 2023 | -73.27% |
| Sep 30, 2023 | -516.68% |
| Jun 30, 2023 | -228.57% |
| Mar 31, 2023 | -267.34% |
| Dec 31, 2022 | -234.89% |
| Sep 30, 2022 | -986.38% |
| Jun 30, 2022 | -447.92% |
| Mar 31, 2022 | -401.04% |
| Dec 31, 2021 | -1,134.55% |
| Sep 30, 2021 | -34.37% |